Abstract: A rare earth permanent magnet includes a main phase containing: a rare earth element R of one or more types including Nd; an element L of one or more types selected from a group consisting of Co, Be, Li, Al, and Si; B; and Fe, wherein crystals which form the main phase belong to P42/mnm; some of B atoms occupying a 4f site of the crystals are substituted with atoms of the element L; each distribution of Nd atoms and the atoms of the element L appears along a C-axis direction of the crystals in a plurality of cycles; and the rare earth permanent magnet includes an area where a cycle of the atoms of the element L matches a cycle of the Nd atoms.

Abstract: A method of manufacturing an Sm—Fe—N magnet includes a sealing step of filling a metal sheath with a magnet powder including an Sm—Fe—N compound as a main component and sealing the metal sheath, a Magnetic field applying step of applying a magnetic field to the magnet powder sealed in the metal sheath, and magnetizing the magnet powder by magnetically orienting the magnet powder and aligning a direction of magnetic orientation in one direction, a preliminary rolling step of preliminarily rolling the magnetically oriented magnet powder sealed in the metal sheath to make the magnetically oriented magnet powder into a green compact, and a pressurizing step of pressurizing the green compact sealed in the metal sheath and densifying the green compact to form a magnet body, wherein in the preliminary rolling step, the preliminary rolling is performed by lightly rolling the magnetically oriented magnet powder sealed in the metal sheath with a pressure smaller than a pressure in the pressurizing step.

Abstract: A magnetic property of a rare earth permanent magnet containing neodymium, iron, and boron is enhanced. The present disclosure is a rare earth permanent magnet with a compound represented by a following expression as a main phase: Nd2Fe14B(1-x)Mx. In the expression, M represents an element selected from any one of cobalt, beryllium, lithium, aluminum, and silicon and x satisfies 0.01?x?0.25. The main phase has an Nd—Fe—B layer and an Fe layer periodically and part of boron is substituted with any one or more types of elements selected from a group consisting of cobalt, beryllium, lithium, aluminum, and silicon.

Abstract: A rare earth permanent magnet includes a main phase containing: a rare earth element R of one or more types including Nd; an element L of one or more types selected from a group consisting of Co, Be, Li, Al, and Si; B; and Fe, wherein crystals which form the main phase belong to P42/mnm; some of B atoms occupying a 4f site of the crystals are substituted with atoms of the element L; each distribution of Nd atoms and the atoms of the element L appears along a C-axis direction of the crystals in a plurality of cycles; and the rare earth permanent magnet includes an area where a cycle of the atoms of the element L matches a cycle of the Nd atoms.

Abstract: A system capable of designing an optimum administration form of a magnetic drug is provided. The system determines first information about an side-effect-related organ on which a magnetic drug produces a side effect, based on equipment analysis information after administering the magnetic drug; further determines second information about a drug-efficacy-related organ in which drug efficacy of the magnetic drug should be demonstrated; evaluates the administration form of the magnetic drug based on the first information and the second information; corrects the administration form of the magnetic drug based on an evaluation result; and outputs information of the corrected administration form.

Abstract: A metal-salen complex compound, which exhibits excellent noninvasiveness and can be efficiently transferred to an affected site, a local anesthetic containing this metal-salen complex compound, and an antineoplastic drug containing this metal-salen complex compound are provided. Regarding the metal-salen complex compound, a metal atom part in each of two molecules of a metal-salen complex or a derivative of the metal-salen complex is dimerized via water, and the metal-salen complex compound is mixed with a base to produce an ointment.

Abstract: The present invention provides a drug delivery system that overcomes conventional technical problems and that is readily put to practical use. Iron-salen complexes represented by General Formula (I) below. The invention renders iron-salen complexes magnetic, which can thus be used as drugs that can be delivered to affected areas in the body using the inherent magnetic properties of the drug without employing carriers composed of magnetic substances as has been done hitherto.

Abstract: [Object] An anticancer agent capable of continuously killing cancer cells in a plurality of phases is provided. [Solution] An anticancer agent contains a complex produced by making a metal-salen complex compound, which includes a central metal and (N, N, O, O) as a quadridentate ligand and is magnetic, bind to taxane molecules which are anticancerous; and the anticancer agent is to kill cancer cells regarding which phase transition of its cell cycle occurs between phases including Gap1, Synthesis, Gap2, and Mitosis and Cytokinesis. The present disclosure is suited for use to kill cancer cells of breast cancer and, particularly, cancer cells of triple-negative breast cancer. The present disclosure is designed to make the anticancer agent contact the cancer cells in two or more continuous phases selected from a group consisting of Gap1, Synthesis, Gap2, and Mitosis and Cytokinesis and kill the cancer cells.

Abstract: A rare earth permanent magnet comprising a main phase containing: one or more elements R selected from a group consisting of Nd and Pr; one or more elements L selected from a group consisting of Co, Be, Li, Al and Si; one or more elements A selected from a group consisting of Tb, Sm, Gd, Ho and Er; Fe; and B, wherein crystals forming the main phase belong to P42/mnm, and some B atoms occupying a 4f site are substituted by atoms of the elements L.

Abstract: [object] A magnetization technique that enhances magnetic properties of an organic compound is provided without damaging properties of the organic compound or while maintaining the structure of the organic compound. [solution] The present disclosure is a method for manufacturing a magnetic substance composed of crystals of a magnetization target compound and an electron acceptor by combining the magnetization target compound with the electron acceptor; forming a solution by dissolving a mixture of the magnetization target compound and the electron acceptor in a solvent; maintaining the solution in a very low temperature state and allowing the solution to deposit the crystals of the magnetic target compound and the electron acceptor; and separating the crystals from the solvent.

Abstract: [Object] An anticancer agent capable of continuously killing cancer cells in a plurality of phases is provided. [Solution] An anticancer agent contains a complex produced by making a metal-salen complex compound, which includes a central metal and (N, N, O, O) as a quadridentate ligand and is magnetic, bind to taxane molecules which are anticancerous; and the anticancer agent is to kill cancer cells regarding which phase transition of its cell cycle occurs between phases including Gap1, Synthesis, Gap2, and Mitosis and Cytokinesis. The present disclosure is suited for use to kill cancer cells of breast cancer and, particularly, cancer cells of triple-negative breast cancer. The present disclosure is designed to make the anticancer agent contact the cancer cells in two or more continuous phases selected from a group consisting of Gap1, Synthesis, Gap2, and Mitosis and Cytokinesis and kill the cancer cells.

Abstract: A metal-salen complex derivative with an excellent yield and stability is provided and a method for producing such a metal-salen complex derivative is provided. The present invention provides: metal-salen complex derivative obtained by allowing a target component composed of at least one of an enzyme, an antibody, an antigen, a peptide, an amino acid, an oligonucleotide, a protein, a nucleic acid, and a medical molecule to bind to a metal-salen complex via an amide bond or a disulfide bond; a method for producing such a metal-salen complex derivative.

Abstract: A new self-magnetic metal-salen complex compound and its derivatives are provided. The present invention is a metal-salen complex compound including any one of the following compounds.

Abstract: A drug using the magnetic properties of a metal salen complex as represented by the following general formula in order to magnetize the intended drug by chemically binding the drug to a metal salen complex so that the drug can be delivered to the target diseased site. The drug can be delivered to the diseased site using the magnetic properties of the drug per se without using a carrier made of a magnetic substance as in the conventional methods.

Abstract: A magnetic property of a rare earth permanent magnet containing neodymium, iron, and boron is enhanced. The present disclosure is a rare earth permanent magnet with a compound represented by a following expression as a main phase: Nd2Fe14B(1-x) Mx In the expression, M represents an element selected from any one of cobalt, beryllium, lithium, aluminum, and silicon and x satisfies 0.01?x?0.25. The main phase has an Nd—Fe—B layer and an Fe layer periodically and part of boron is substituted with any one or more types of elements selected from a group consisting of cobalt, beryllium, lithium, aluminum, and silicon.

Abstract: A metal-salen complex compound responsive drug, which has an antidotal property capable of neutralizing cytotoxicity of a metal-salen complex compound, and an intra-corporeal behavior control system for the metal-salen complex compound are provided. This metal-salen complex compound responsive drug contains an effective amount of a metal chelating agent to suppress side effects by the metal-salen complex compound.

Abstract: The present disclosure relates to a ferromagnetic substance containing a crystal of a metal complex molecule in which a heterocycle is bonded to metal, the metal of the metal complex molecule is bonded to the metal of another metal complex via oxygen as a electron donor, and the ferromagnetic substance has a ferromagnetic property balanced with stability of crystals based on a metal-electron donor-metal bond angle that is from 130° to 160°. The present disclosure also relates to a drug containing, as a principal component, the crystal of the metal complex molecule.

Abstract: A metal-salen complex compound, which exhibits excellent noninvasiveness and can be efficiently transferred to an affected site, a local anesthetic containing this metal-salen complex compound, and an antineoplastic drug containing this metal-salen complex compound are provided. Regarding the metal-salen complex compound, a metal atom part in each of two molecules of a metal-salen complex or a derivative of the metal-salen complex is dimerized via water, and the metal-salen complex compound is mixed with a base to produce an ointment.

Abstract: A new radical inhibitor, a composition containing the new radical inhibitor, and a radical generation inhibition method using the new radical inhibitor are provided. A radical inhibitor according to the present invention contains a salen complex compound of a bivalent metal.

Abstract: The present invention provides a drug delivery system that overcomes conventional technical problems and that is readily put to practical use. Iron-salen complexes represented by General Formula (I) below. The invention renders iron-salen complexes magnetic, which can thus be used as drugs that can be delivered to affected areas in the body using the inherent magnetic properties of the drug without employing carriers composed of magnetic substances as has been done hitherto.